Christopher H. Domen

Cognitive Safety Data from a Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase <scp>IIb</scp> Study of the Effects of a Cannabidiol and <scp>Δ9</scp>‐Tetrahydrocannabinol Drug on Parkinson's Disease‐Related Motor Symptoms

Christopher H. Domen, Stefan Sillau, Ying Liu et al. · Movement Disorders · 2023 · 33 citations · Full text

Medicine, Neurology, Pharmacology +16

Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal

Laura J. Weinkle, Christopher H. Domen, Ian T. Shelton et al. · Multiple Sclerosis and Related Disorders · 2018 · 24 citations

Law, Health Law, Neurology +14

Higher Risk, Higher Reward? Self‐Reported Effects of Real‐World Cannabis Use in Parkinson's Disease

Samantha K. Holden, Christopher H. Domen, Stefan Sillau et al. · Movement Disorders Clinical Practice · 2022 · 23 citations · Full text

Medicine, Pharmacology, Psychiatry +14

Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial

Ying Liu, Jacquelyn Bainbridge, Stefan Sillau et al. · Movement Disorders · 2024 · 19 citations · Full text

Medicine, Neurology, Pharmacology +14

The APPCN multisite didactic initiative: Development, benefits, and challenges

Christopher H. Domen, Robert L. Collins, Jeremy J. Davis · The Clinical Neuropsychologist · 2020 · 13 citations

Medicine, Medical Education, Clinical Neuroscience +10